# A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses

> **NCT06693362** · PHASE1 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Severe Viral Pneumonia(Not Include COVID-19)

## Interventions

- **DRUG:** Placebo
- **DRUG:** Drug therapy
- **OTHER:** Standard Treatment

## Key facts

- **NCT ID:** NCT06693362
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-20
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-12-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06693362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06693362, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06693362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*